Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen

Santhera has exercised its option on non-hormonal steroid modulator vamorolone, giving it control of a Duchenne muscular dystrophy (DMD) asset it thinks can rack up annual sales of more than $500 million.